Advanced Filters
noise

Atopic Dermatitis Clinical Trials

A listing of Atopic Dermatitis medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 235 clinical trials
H Hong

Phase 2 Randomized Double-blind Study to Assess Topical Zabalafin Hydrogel Vs Vehicle in Mild to Moderate AD.

A Phase 2b study investigating the efficacy of zabalafin in people with mild to moderate atopic dermatitis (eczema).

2 years of age All Phase 2

A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis

The purpose of this study is to evaluate the efficacy and safety of different dose regimens of IMG-007, compared to placebo.

18 - 74 years of age All Phase 2
C Corvus Clinical Operations

Study to Evaluate Soquelitinib in Participants With Moderate to Severe AD

The main purpose of this study is to see how well different doses of soquelitinib work in participants with atopic dermatitis (AD) as compared to a placebo (pill with no medicine in it). To check this, the study doctors will examine participants' skin regularly to track how their AD changes …

18 years of age All Phase 2
I Irma M Richardon, MHA

Topical Treatment for Atopic Dermatitis

Medication adherence is a poorly studied phenomenon that challenges both patients and physicians. 50% of individuals with chronic disease are not adherent to their medication regimen. Within the United States, non-adherence to medical treatment leads to approximately $100 billion in hospital admission costs. While the issue of adherence is not …

9 years of age All Phase N/A
H Hu Wei, Doctor

A Study of BBT001 in Healthy Volunteers (HVs) and in Adult Patients With Moderate to Severe Atopic Dermatitis (AD)

This is a Phase 1, randomized, blinded, placebo controlled, single ascending dose (SAD) study of BBT001 in healthy volunteers (HVs) and adult patients with moderate to severe Atopic Dermatitis (AD).

18 - 65 years of age All Phase 1
F For more information at the NIH Clinical Center contact Office of Patient Recruitment (OPR)

Effects of Treatments on Atopic Dermatitis

Background \- Atopic dermatitis, or eczema, is a chronic skin disorder. Patients sometimes have infections with S. aureus bacteria. Researchers want to study how eczema treatments affect the number and the type of bacteria on the skin. Objectives \- To study the effect of eczema treatments on skin bacteria. Eligibility …

2 - 50 years of age All Phase 2
L Lisa Beck, MD

Skin Microbial Ecology in Atopic Dermatitis

Everybody's skin has bacteria that normally lives on it. Previous research has shown that people with eczema (or atopic dermatitis \[AD\]) have much higher concentrations of a certain bacteria (S. aureus), especially when their disease is active but little is known about the role that this bacteria plays in psoriasis …

13 years of age All Phase N/A
L Laurent MISERY, Professor

Study of Alloknesia in Atopic Dermatitis

Alloknesia is defined as pruritus (= itching) triggered by light mechanical stimuli, which are responsible for the perception of light touch under physiological conditions, but which are perceived as pruritic under pathological conditions. Alloknesia occurs mainly in the context of chronic pruritus. Consequently, patients suffering from chronic pruritus frequently perceive …

18 years of age All Phase N/A
M Ms. Chen

Herbal Ointment in Treating Atopic Dermatitis Topically

Atopic dermatitis (AD), also known as atopic eczema, is a chronic inflammatory skin disorder. The current first-line recommended treatment for AD is the use of emollients, topical corticosteroids (TCS), and oral antihistamines if necessary. However, patients often have side effects like skin atrophy and telangiectasia. And there were plenty of …

18 - 65 years of age All Phase 2/3
E Elise Nelson

Dupixent and Narrowband UVB for Atopic Dermatitis

24 weeks open-label study with dupilumab and narrowband UVB phototherapy three times weekly for 12 weeks followed by 12 weeks of dupilumab monotherapy.

18 years of age All Phase 4

Simplify language using AI